With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking to its projection to generate sales of more than 40 billion pounds sterling ...

The European Medicines Agency (EMA) has accepted for review GSK’s marketing authorisation application (MAA) for Blenrep (belantamab mafodotin), an antibody-drug conjugate (ADC), to treat ...

After Blenrep’s approval in 2020, the FDA has since cleared two BCMA-targeted CAR-T therapies: Bristol Myers and 2seventy bio’s Abecma in 2021 and J&J and Legend Biotech’s Carvykti in 2022.

Blenrep is a humanized, afucosylated, IgG1 anti-B cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent, monomethyl auristatin F. The Food and Drug Administration ...

Key Takeaways Blenrep plus Velcade and dexamethasone significantly improves overall survival in relapsed/refractory multiple myeloma compared to Darzalex-based regimens. The DREAMM-7 trial met its ...

Blenrep was given a conditional approval by the FDA a few months later as a fifth-line therapy for MM, and (see that second post linked above) this was tied to the results holding up in a ...

Treatment of Blenrep (belantamab mafodotin) in combination with Velcade (bortezomib) plus dexamethasone significantly improved progression-free survival compared with standard treatment for patients ...

During the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) meeting this July, the CHMP recommended the approval of two biologics and one biosimilar: GlaxoSmithKline’s Blenrep ...

However, in November 2022, Blenrep was withdrawn from the U.S. market after the failure of GSK’s phase III confirmatory study, DREAMM-3, which evaluated Blenrep in patients with relapsed or ...

(Reuters) -The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood plasma cells, the British drugmaker said on Thursday. EU ...

BLENREP is a first-in-class anti-BCMA (B-cell maturation antigen) therapy for patients whose disease has progressed despite prior treatment with an immunomodulatory agent, proteasome inhibitor and ...

The FDA granted accelerated approval to belantamab mafodotin-blmf for treatment of relapsed or refractory multiple myeloma. Belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline) — an anti-B-cell ...